To compare the effectiveness of Rivaroxaban vs standard of care (low molecular weight heparin, unfractionated heparin, and warfarin) in patients with Pulmonary embolism

Trial Profile

To compare the effectiveness of Rivaroxaban vs standard of care (low molecular weight heparin, unfractionated heparin, and warfarin) in patients with Pulmonary embolism

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Low molecular weight heparin; Warfarin
  • Indications Pulmonary embolism
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Jan 2017 New trial record
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top